|
Jula 2015
|
12 weeks
|
Dyslipidemia patients
|
120 (60/60)
|
48.4 ± 6.2
|
48.0 ± 6.2
|
100
|
100
|
Serum CoQ 10 concentrations
|
|
Oranje 2001
|
3 months
|
Type 2 diabetes patients
|
19 (9/10)
|
64 ± 8
|
63 ± 8
|
100
|
70
|
Plasma CoQ 10 concentrations
|
|
Päivä 2005
|
8 weeks
|
Dyslipidemia patients
|
48 (32/16)
|
31–69
|
31–69
|
N
|
N
|
Plasma CoQ 10 concentrations
|
|
Strey 2005
|
6 weeks
|
Heart failure (NYHA II or III) with LVEF < 40%
|
48 (24/24)
|
N
|
N
|
N
|
N
|
Plasma CoQ 10 concentrations
|
|
Mortensen 1997
|
6 weeks
|
Dyslipidemia patients
|
45 (23/22)
|
52.9 (32,69)
|
54.8 (42,67)
|
60.9
|
40.9
|
Serum CoQ 10 concentrations
|
|
Morrison 2017
|
24 weeks
|
Patients with HIV
|
147 (71/75)
|
45 (41,51)
|
47 (39,53)
|
81
|
76
|
Plasma CoQ 10 concentrations
|
|
McMurray 2010
|
3 months
|
Heart failure (NYHA II or III) with LVEF < 40%
|
1103 (551/552)
|
N
|
N
|
N
|
N
|
Serum CoQ 10 concentrations
|
|
Ghirlanda 1993
|
3 months
|
Dyslipidemia patients
|
30 (20/10)
|
47 ± 8; 49 ± 10
|
47 ± 8
|
60; 50
|
70
|
Plasma CoQ 10 concentrations
|
|
Chitose 2014
|
6 months
|
STEMI patients
|
75 (38/37)
|
64.1 ± 11.8
|
65.8 ± 12.4
|
73.7
|
75.7
|
Plasma CoQ 10 concentrations
|
|
Berthold 2006
|
14 days
|
Healthy subjects
|
48 (24/24)
|
31.9 ± 8.8
|
28.6 ± 6.6
|
N
|
N
|
Plasma CoQ 10 concentrations
|
|
Barry 2001
|
4 weeks
|
Healthy subjects
|
24 (12/12)
|
26 ± 5
|
26 ± 5
|
41.7
|
41.7
|
Plasma CoQ 10 concentrations
|
|
Ashton et al. 2011
|
26 weeks
|
Heart failure (NYHA II or III) with LVEF < 40%
|
69 (32/37)
|
N
|
N
|
N
|
N
|
Plasma CoQ 10 concentrations
|
